HR-5520-115
Placed on the Union Calendar, Calendar No. 533.
What it does
This bill would authorize the Department of Veterans Affairs (VA) to conduct and fund research on whether cannabis is safe and effective for veterans enrolled in the VA health care system who have been diagnosed with conditions such as chronic pain or post-traumatic stress disorder (PTSD). It would also require that data collected during this research be stored in a way that makes it available for future study.
Who benefits
Veterans enrolled in the VA health care system — particularly the roughly 4–5 million who report chronic pain and the estimated 500,000+ diagnosed with PTSD — would potentially benefit from expanded treatment options if research yields positive findings. VA researchers and medical staff would gain new authority and funding to study cannabis-based treatments. Academic and medical institutions partnering with the VA on research would also benefit.
Who is hurt
Pharmaceutical companies that produce existing pain management and PTSD medications (e.g., opioids, antidepressants, anti-anxiety drugs) could face reduced demand if cannabis research produces favorable results and leads to broader VA prescribing. Federal law enforcement and drug policy agencies may face institutional friction, as cannabis remains a Schedule I controlled substance under the Controlled Substances Act, creating potential conflicts for VA personnel conducting the research. Some veterans and advocacy groups who oppose cannabis use on moral, health, or practical grounds may object to VA resources being directed toward this research area.
Supporters argue
Supporters argue that veterans suffering from chronic pain and PTSD deserve access to every evidence-based treatment option available, and that the VA has a duty to rigorously study promising therapies rather than leave veterans to seek them outside the federal health system. They contend that existing treatments — including opioid-based pain medications — carry serious risks, including addiction and overdose, and that cannabis may offer a safer alternative for some patients. Supporters also argue that authorizing formal VA research would produce high-quality, peer-reviewed data that currently does not exist at scale, allowing future medical decisions to be grounded in science rather than assumption. Finally, they note that many states have already legalized medical cannabis, meaning veterans in those states are already using it — often without any medical guidance from their VA providers.
Opponents argue
Opponents argue that cannabis remains a Schedule I controlled substance under federal law — meaning it is classified as having no accepted medical use and a high potential for abuse — and that directing a federal agency to research it creates a direct conflict with existing federal drug law and policy. They contend that the VA's limited research budget and personnel should be focused on treatments with stronger existing evidence bases, rather than a substance whose long-term health effects, particularly on the brain, are still not well understood. Opponents also raise concerns that VA-sponsored research could be perceived as a federal endorsement of cannabis use, potentially accelerating legalization efforts before the science is settled. Some also argue that existing non-VA research pathways — such as through the National Institutes of Health or academic medical centers — are better suited to conduct this research without implicating federal drug enforcement policy.
Constitutional context
The bill implicates the Spending Clause (Art. I, Sec. 8), which gives Congress broad authority to direct how federal funds are spent, including through the VA. It also touches on the Supremacy Clause and the Controlled Substances Act (CSA), as cannabis is a Schedule I drug under federal law — a tension that has not been definitively resolved by the courts in the context of federal agency research. The Commerce Clause underpins Congress's authority to regulate controlled substances nationally, as established in Gonzales v. Raich (2005). The Take Care Clause (Art. II, Sec. 3) is relevant insofar as the executive branch must enforce existing federal drug law while simultaneously being authorized by this bill to study a Schedule I substance.
Checks and balances
The bill would expand executive branch authority by granting the VA — an executive agency — new discretionary power to conduct and fund cannabis research. Congress retains oversight through the appropriations process, as the VA would need funding to carry out the research. The requirement to preserve collected data for future research adds a modest accountability mechanism, keeping Congress and the public informed of findings over time.
Historical precedent
The VA Research Enhancement Act and various NDAA provisions have previously directed the VA to study specific medical treatments. More directly, the Rohrabacher–Blumenauer Amendment (annually renewed since 2014) has restricted DOJ from interfering with state medical cannabis laws, reflecting ongoing congressional navigation of the federal-state cannabis conflict.